Novo Nordisk's dropping share price spells the end for CEO
Novo Nordisk's chief executive Lars Fruergaard Jørgensen is stepping down by "mutual agreement" with the company's board.
Incyte's PD-1 drug brings immunotherapy to anal cancer
Incyte has broken new ground in immuno-oncology, getting FDA approval for its Zynyz drug as a treatment for anal cancer
Pathos AI's big $365m Series D, and other bio financings
Our round-up of recent biotech financings includes rounds for Pathos AI, Stylus Medicine, Haya Therapeutics, Therini Bio and Tiltbio.
Datavant, Aetion merger creates real-world data force
Datavant and Aetion merger promises "faster, more actionable" real-world data insights across pharma's clinical and commercial lifecycle.
World first as infant gets personalised CRISPR therapy
In a medical breakthrough, a child diagnosed with a rare genetic disorder has received a bespoke CRISPR gene editing therapy to correct the mutation.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
4th Annual Process Development for Cell Therapies Summit
Driving Process Robustness, Scalability, Speed & Affordability
Operationalize: Expanded Access Programs comes to the West C...
Improving Global Access to Life-Changing Therapeutics...
Injectable Drug Delivery 2025 – Driving Innovation Through C...
Press Release: Injectable Drug Delivery 2025 – Driving Innovation Through Collaboration LONDON, UK – 24–25 June 2025
4th In Vivo Cell Engineering & Gene Editing Summit
This forum brings together the brightest minds from biopharma, academia, and regulatory leadership to explore the full translational journey
6th Gene Therapy Analytical Development Summit Europe
Join 24+ expert speakers and over 90 industry stakeholders to unlock analytical strategies that elevate your development programmes,...